Interestingly, blocking RIPK1 by Nec-1s in vivo and in vitro dramatically alleviates colitis and cell death, which share the same phenotype with ABIN1 overexpression; hence, ABIN1 activation may be considered a therapeutic strategy for UC [138]. Here, RIPK1 is linked to colitis.